NCT00082888 - Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 24, 2004

Primary Completion Date

May 20, 2009

Study Completion Date

July 5, 2017

Conditions

Anaplastic Large Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueMature T-Cell and NK-Cell Non-Hodgkin LymphomaNodal Marginal Zone LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone Lymphoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tipifarnib

Given PO

Trial Locations (2)

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic, Rochester

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH